Director, Global Market Access Strategy, RWE, HEOR and Pricing

Director, Global Market Access Strategy, RWE, HEOR and Pricing

VN879

Permanent

Gaithersburg, MD, Oxford, UK

Commercial

The Director will be a core strategic leader and member of the global Market Access team responsible for shaping and executing the global Market Access, Health Technology Assessment (HTA), pricing, and evidence generation strategies, encompassing Real World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) for KIMMTRAK (tebentafusp). The geography covers 40+ countries and includes collaborations with Immunocore’s commercial partners for Central and Eastern Europe, Canada, Australia, LATAM, Turkey and MEA.

The Director will work closely with Medical Affairs and other global functions to build upon KIMMTRAK’s success by driving the long‑term Market Access strategy for RWE generation and HEOR projects, and publication with an emphasis on expansion of capabilities for the USA market in oncology

The Director will be an entrepreneurial, highly curious and collaborative leader. They must be resourceful with a ‘sleeves rolled up’ attitude and able to forge strong ties across the organisation. They will combine strong strategic thinking and analytical skills with the ability to translate complex evidence and market insights into clear access strategies, options and trade‑offs for senior leadership. The candidate will bring strong leadership and publication record supporting commercialised and innovative product launches in oncology with an exceptional track record of promoting cross‑functional collaboration across the R&D, Commercial and Medical functions.

They will act as a trusted advisor to senior leaders on Market Access, HTA and pricing issues, able to challenge assumptions and shape strategic decisions with robust payer and evidence‑based insights. The successful candidate will report to the Head of Market Access and HEOR and support the Heads of European, International and partnership Markets, and the US Commercial and Medical Affairs teams.

The Director will also be accountable for preparation for the next indications of KIMMTRAK, including designing and leading HTA strategies, overseeing pricing and reimbursement for specific countries and is expected to act as the subject matter expert for internal planning of evidence needs of the Immunocore pipeline for HTA, pricing and reimbursement. They will provide early strategic input into target product profiles and clinical development plans to optimise the probability of favourable HTA and reimbursement outcomes.

They will represent the Immunocore at meetings with government authorities and coordinate with multiple internal functions, including Commercial, Medical, Clinical Development, Regulatory, Biostats and Project Management to achieve reimbursement of KIMMTRAK, globally. The individual will also liaise with Finance, Legal and Procurement to ensure compliance and invoice reconciliation for country‑level budgets.

The role will include significant autonomy, exposure to the Immunocore executive team and an opportunity to develop skills at all levels of the Market Access, RWE and HEOR function to drive global and in‑country success of KIMMTRAK. The successful individual is expected to expand their expertise and responsibilities as Immunocore grows with the launch of new indications for KIMMTRAK and new assets.

They will play a key role in informing portfolio, indication sequencing and lifecycle management decisions from a Market Access and payer value perspective and drive evidence generation after launch.

• Define and own the global RWE and HEOR strategy and capabilities for KIMMTRAK and Immunocore’s oncology portfolio, ensuring…